Almonds for Vitamin E and Diet Quality in People Taking GLP-1 Medicines
Tests daily almonds in people with obesity or type 2 diabetes using GLP-1 treatment.
Plain-language title generated from the registry record
Registry title: Ability of Almonds to Improve Nutrition During GLP-1 Treatment
Key facts
- Where
- Baton Rouge, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 with obesity or type 2 diabetes who are prescribed injectable semaglutide or tirzepatide. It tests whether eating almonds improves vitamin E levels and diet quality.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Obesity (BMI ≥ 30 kg/m2), or type 2 diagnosed by a doctor with BMI ≥ 27 kg/m2 - 47.5 kg/m2.
- Earlier treatment
- Prescribed branded injectable semaglutide or injectable tirzepatide, with at least a two-month supply. Baseline tests must be done before starting it. No GLP-1 medication in the last 3 months.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Taking or planning a medication, vitamin or mineral supplement that affects vitamin E levels
- Allergic to almonds
- History of bariatric surgery
- Active malignancy, except some skin cancers, or chemotherapy/radiotherapy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07796204, who can take part
Where in United States
- Pennington Biomedical Research CenterBaton Rouge, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pennington Biomedical Research Center
- Trial code
- NCT07796204
- Record updated
- 1 September 2026
- Original description
This 8-week randomized controlled pilot trial is to test the hypothesis that, compared to a Usual Diet control group, almond intake will increase vitamin E (alpha-tocopherol) levels in the blood and improve diet quality (Healthy Eating Index) among people prescribed a glucagon-like peptide-1. Two groups of individuals will either: 1) consume a minimum of 56 grams of almonds each day, or 2) not consume almonds and follow their usual diet.Read full original descriptionShow less
The Ability of Almonds to Increase Vitamin E (Alpha-tocopherol) and Diet Quality During GLP-1 Treatment: A Randomized Controlled Pilot Trial
This 8-week randomized controlled pilot trial is to test the hypothesis that, compared to a Usual Diet control group, almond intake will increase vitamin E (alpha-tocopherol) levels in the blood and improve diet quality (Healthy Eating Index) among people prescribed a glucagon-like peptide-1. Two groups of individuals will either: 1) consume a minimum of 56 grams of almonds each day, or 2) not consume almonds and follow their usual diet.
Inclusion: Adults aged 18-70 years; BMI ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication; Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study); HbA1c will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria; Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator; Enroll and complete baseline assessments prior to starting pharmacotherapy; Able and willing to adhere to all study-related procedures.
Exclusion: Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels; Previous use of a glucagon-like peptide-1 medication in the last 3 months; Contraindications to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication; Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure; History of bariatric surgery; Allergic to almonds; Active malignancy, excluding some skin cancers, or undergoing chemotherapy/radiotherapy; Pregnancy or breastfeeding.